In this first worldwide randomized trial for newly diagnosed Philadelphia-positive ALL, what was the chemo-free experimental arm regimen?
Imatinib plus blinatumomab
Ponatinib (dose-adjusted by age) followed by blinatumomab
Dasatinib plus rituximab